- GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
- GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
- GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
- GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
- GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
- GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
- GeoVax Addresses Identification of New Mpox Variant
- GeoVax Announces Addition of Renowned Global Experts to its Scientific Advisory Board
- GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin® Gene Therapy
- GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin® in Recurrent Head & Neck Cancer
- GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
- GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
- GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
- GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
- GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
- BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
- GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients with Recent Clinical Data for GEO-CM04S1
- GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
- GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
- GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025
- GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions
- GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025
- GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
- GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit
- GeoVax Labs Announces $2.5 Million Registered Direct Offering
- GeoVax Comments on U.S. “America First Global Health Strategy” and Highlights Company’s Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security
- GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications
- GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations
- GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
- GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference
- GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference
- GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences
- GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
- GeoVax to Present at the Emerging Growth Conference on August 20, 2025
- GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
- GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
- GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
- GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
- GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
- GeoVax to Advance Gedeptin(R) into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
- GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
- GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
- GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
- GeoVax to Present at the Emerging Growth Conference on July 16, 2025
- GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
- GeoVax Responds to Growing Mpox Threat with Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives
- GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
- GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
- GeoVax Comments on FDA Approval of Keytruda® in Head and Neck Cancer, Underscoring Potential for Gedeptin® Combination Therapy
